A five-year follow-up clinical study of the B cell maturation antigen chimeric antigen receptor-T cell therapy HDS269B in patients with relapsed or refractory multiple myeloma.
Dongjian ChenYu ZhuZhi ChengSongfu JiangHaiyan HeWan-Ting QiangFang XiangXuedong SunJuan DuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
HDS269B is effective and safe, especially for patients with ECOG 0-2. Early CAR-T cell intervention may improve prognosis in patients with RRMM.